EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: TD Cowen 46 th Annual Health Care Conference Forum: Fireside Chat Date: March 3, 2026Time: 2:30 p.m.

GlobeNewsWire • 12 hours ago

EyePoint Appoints Michael Campbell as Chief Commercial Officer

– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma – – Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis ® and Xiidra ® –

GlobeNewsWire • Feb 18, 2026

EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?

EyePoint (EYPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Feb 18, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

GlobeNewsWire • Feb 17, 2026

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.

24/7 Wall Street • Feb 16, 2026

EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that George O.

GlobeNewsWire • Feb 5, 2026

EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME program first patient dosing expected in Q1 2026 – – Presenting at the 44 th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m.

GlobeNewsWire • Jan 7, 2026

EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know

Does EyePoint (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Dec 22, 2025

3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026

EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.

Zacks Investment Research • Dec 22, 2025